Logos Global Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Logos Global Management LP reported 38 stock positions worth $562.5 million. Its top holding was Ideaya Biosciences (IDYA) at 10.2% of the portfolio, followed by Revolution Medicines (RVMD, 10.1%) and Akero Therapeutics (AKRO, 8.6%). Compared with Q4 2024, it opened 11 new positions, sold out of 19, added to 10 and reduced 6. The biggest buy was a new position in Nuvalent Class A (NUVL) and the biggest sale an exit from Cytokinetics (CYTK).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $562.5M (Q1 2025)
- SEC Filing
- 0001172661-25-002012 ↗ filed May 15, 2025
Holdings Value
Holdings 38 stocks · $562.5M
| IDYA Ideaya Biosciences Inc. | 10.19% | 3,500,000 | $57.3M | Add +16.7% |
| RVMD Revolution Medicines Inc. | 10.06% | 1,600,000 | $56.6M | Add +10.3% |
| AKRO Akero Therapeutics Inc. | 8.64% | 1,200,000 | $48.6M | Add +50.0% |
| JANX Janux Therapeutics Inc. | 7.92% | 1,650,000 | $44.5M | Add +32.0% |
| NUVL Nuvalent Inc. Class A | 6.30% | 500,000 | $35.5M | New |
| TEVA Teva Pharmaceutical-SP ADR | 4.64% | 1,700,000 | $26.1M | New |
| XENE Xenon Pharmaceuticals Inc. | 3.88% | 650,000 | $21.8M | New |
| KROS Keros Therapeutics Inc. | 3.62% | 2,000,000 | $20.4M | New |
| IRON Disc Medicine Inc. | 3.48% | 394,342 | $19.6M | Add +97.2% |
| BNTX Biontech SE-ADR | 3.24% | 200,000 | $18.2M | Reduce -33.3% |
| ETNB 89BIO Inc. | 3.23% | 2,500,000 | $18.2M | New |
| SLNO Soleno Therapeutics Inc. | 3.18% | 250,000 | $17.9M | Reduce -28.6% |
| ERAS Erasca Inc. | 3.17% | 13,000,000 | $17.8M | Add +4.0% |
| OCUL Ocular Therapeutix Inc. | 3.00% | 2,300,000 | $16.9M | Reduce -34.3% |
| DSGN Design Therapeutics Inc. | 2.89% | 4,217,627 | $16.3M | No change |
| MLTX Moonlake Immunotherapeutics | 2.43% | 350,000 | $13.7M | New |
| GERN Geron Corp. | 2.26% | 8,000,000 | $12.7M | Add +300.0% |
| OLMA Olema Pharmaceuticals Inc. | 2.14% | 3,208,875 | $12.1M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 2.09% | 350,000 | $11.7M | New |
| RNAM Avidity Biosciences Inc. | 1.84% | 350,000 | $10.3M | New |
| MAZE Maze Therapeutics Inc. | 1.83% | 936,914 | $10.3M | New |
| ANNX Annexon Inc. | 1.37% | 4,000,000 | $7.7M | Add +56.9% |
| GPCR Structure Therapeutics Inc. | 1.31% | 425,000 | $7.4M | Reduce -39.3% |
| CMPS Compass Pathways PLC | 1.02% | 2,000,000 | $5.7M | New |
| DYN Dyne Therapeutics Inc. | 0.93% | 500,000 | $5.2M | Add +11.1% |
| ELVN Enliven Therapeutics Inc. | 0.84% | 240,000 | $4.7M | Add +71.4% |
| IMVT Immunovant Inc. | 0.84% | 275,000 | $4.7M | Reduce -8.3% |
| AEROVATE THERAPEUTICS INC | 0.62% | 1,400,000 | $3.5M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.60% | 2,222,222 | $3.4M | No change |
| UNICYCIVE THERAPEUTICS INC | 0.52% | 5,078,927 | $2.9M | No change |
| TRVI Trevi Therapeutics Inc. | 0.47% | 424,715 | $2.7M | Reduce -66.0% |
| ATXS Astria Therapeutics Inc. | 0.47% | 500,000 | $2.7M | No change |
| RAPP Rapport Therapeutics Inc. | 0.37% | 208,910 | $2.1M | No change |
| GLYCOMIMETICS INC | 0.20% | 5,400,000 | $1.1M | No change |
| SEPN Septerna Inc. | 0.14% | 134,202 | $777K | No change |
| ALLK Allakos LLC | 0.12% | 2,900,000 | $660K | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.08% | 145,089 | $435K | No change |
| SLDB Solid Biosciences Inc. | 0.07% | 100,000 | $370K | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $16K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $16K | No change |
Total filed on the 13F, all lines: $562.5M.
Portfolio Sells Q4 2024 → Q1 2025
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −4.95 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −4.33 |
| MRUS Merus NV | Sold out | 0.00% | −3.69 |
| INSM Insmed Inc. | Sold out | 0.00% | −3.64 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −3.19 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −2.87 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −2.52 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −2.04 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −2.04 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.87 |
| ALKS Alkermes PLC | Sold out | 0.00% | −1.68 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −1.59 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −1.57 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −1.36 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.25 |
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −1.16 |
| DRUG Bright Minds Biosciences Inc. | Sold out | 0.00% | −1.03 |
| YMAB Y-Mabs Therapeutics Inc. | Sold out | 0.00% | −0.92 |
| GPCR Structure Therapeutics Inc. | Reduce -39.3% | 1.31% | −0.91 |
| BNTX Biontech SE-ADR | Reduce -33.3% | 3.24% | −0.76 |
| OCUL Ocular Therapeutix Inc. | Reduce -34.3% | 3.00% | −0.50 |
| ATYR Atyr Pharma Inc. | Sold out | 0.00% | −0.42 |
| TRVI Trevi Therapeutics Inc. | Reduce -66.0% | 0.47% | −0.13 |
| IMVT Immunovant Inc. | Reduce -8.3% | 0.84% | −0.03 |
| SLNO Soleno Therapeutics Inc. | Reduce -28.6% | 3.18% | +1.33 |
Portfolio Buys Q4 2024 → Q1 2025
| NUVL Nuvalent Inc. Class A | New | 6.30% | +6.30 |
| AKRO Akero Therapeutics Inc. | Add +50.0% | 8.64% | +6.03 |
| TEVA Teva Pharmaceutical-SP ADR | New | 4.64% | +4.64 |
| XENE Xenon Pharmaceuticals Inc. | New | 3.88% | +3.88 |
| KROS Keros Therapeutics Inc. | New | 3.62% | +3.62 |
| ETNB 89BIO Inc. | New | 3.23% | +3.23 |
| RVMD Revolution Medicines Inc. | Add +10.3% | 10.06% | +2.64 |
| MLTX Moonlake Immunotherapeutics | New | 2.43% | +2.43 |
| CRNX Crinetics Pharmaceuticals Inc. | New | 2.09% | +2.09 |
| IRON Disc Medicine Inc. | Add +97.2% | 3.48% | +2.00 |
| RNAM Avidity Biosciences Inc. | New | 1.84% | +1.84 |
| MAZE Maze Therapeutics Inc. | New | 1.83% | +1.83 |
| GERN Geron Corp. | Add +300.0% | 2.26% | +1.43 |
| IDYA Ideaya Biosciences Inc. | Add +16.7% | 10.19% | +1.17 |
| CMPS Compass Pathways PLC | New | 1.02% | +1.02 |
| ELVN Enliven Therapeutics Inc. | Add +71.4% | 0.84% | +0.47 |
| JANX Janux Therapeutics Inc. | Add +32.0% | 7.92% | +0.09 |
| SLDB Solid Biosciences Inc. | New | 0.07% | +0.07 |
| ANNX Annexon Inc. | Add +56.9% | 1.37% | −0.16 |
| DYN Dyne Therapeutics Inc. | Add +11.1% | 0.93% | −0.31 |
| ERAS Erasca Inc. | Add +4.0% | 3.17% | −0.51 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |